entrepreneurs | Science and Enterprise

A new enterprise, spun off from Seattle Children’s Research Institute, is creating therapeutics for diseases from e… https://t.co/CvnMEFT0Cm
about 7 hours ago
New post on Science and Enterprise: Start-Up Developing Engineered B-Cell Therapies https://t.co/vMgdwnIXdi #Science #Business
about 7 hours ago
Global drug maker Roche Group is acquiring an experimental antiviral therapy for Covid-19 infections taken as a ora… https://t.co/e2d7m6HG1E
about 10 hours ago
New post on Science and Enterprise: Roche Gains Covid-19 Oral Drug Candidate https://t.co/nh27g6uCwi #Science #Business
about 10 hours ago
The day that America lost $100 billion because of an immigration visa ban https://t.co/OfEx6SFwxA via @BrookingsInst
about 23 hours ago

Start-Up Developing Engineered B-Cell Therapies

By Alan, on October 22nd, 2020%

A new enterprise, spun off from Seattle Children’s Research Institute, is creating therapeutics for diseases from engineered B-cells in the immune system. . . . → Read More: Start-Up Developing Engineered B-Cell Therapies

Carb-X Funding Nanoscale Sponge to Treat Sepsis

By Alan, on October 21st, 2020%

A company developing tiny particles made of cellular material to soak-up toxins in the body received a $4 million award to advance its sepsis treatment. . . . → Read More: Carb-X Funding Nanoscale Sponge to Treat Sepsis

Growing your Small Business Slowly is Super Important

By Alan, on October 21st, 2020%

Make sure that you don’t grow too quickly or you may end up stunting your own success. . . . → Read More: Growing your Small Business Slowly is Super Important

ALS Drug Shown to Extend Patient Survival

By Alan, on October 16th, 2020%

Results of a clinical trial show a drug to treat amyotrophic lateral sclerosis, or ALS, extends patients’ survival by several months and slows decline of their functions. . . . → Read More: ALS Drug Shown to Extend Patient Survival

Q3 Venture Funds Inch Up, Early-Stage Deals Drop

By Alan, on October 16th, 2020%

Venture capital funding rose in the third quarter of 2020, driven in large part by investments in already established companies rather than newer enterprises. . . . → Read More: Q3 Venture Funds Inch Up, Early-Stage Deals Drop

Cancer Center, Biotech Partner on Off-the-Shelf T-Cells

By Alan, on October 15th, 2020%

MD Anderson Cancer Center and Allogene Therapeutics Inc. agreed to jointly study the company’s cancer treatments derived from donated T-cells. . . . → Read More: Cancer Center, Biotech Partner on Off-the-Shelf T-Cells

Gene Therapy Delivery Tech Licensed in $1.8B Deal

By Alan, on October 14th, 2020%

A biotechnology company creating synthetic viruses with artificial intelligence to deliver gene therapies is licensing its technology to drug maker Roche. . . . → Read More: Gene Therapy Delivery Tech Licensed in $1.8B Deal

Disaster-Proofing Your Business

By Alan, on October 14th, 2020%

Data breaches, compensation claims, and the competition are just three of the other issues that could hold disastrous repercussions for businesses. . . . → Read More: Disaster-Proofing Your Business

Individual Cells Explored with Virtual Reality

By Alan, on October 13th, 2020%

A new software package uses virtual reality to allow biologists and medical researchers to visualize and explore inside individual cells in three dimensions. . . . → Read More: Individual Cells Explored with Virtual Reality

Start-Up Gains Access to Vaccine Nasal Spray Technology

By Alan, on October 12th, 2020%

A company developing techniques to deliver vaccines like Covid-19 with a nasal spray received an opportunity to license the process from University of Houston. . . . → Read More: Start-Up Gains Access to Vaccine Nasal Spray Technology

Science & Enterprise subscription

Specials

Follow us on Twitter

Guest Posts

Please share Science & Enterprise